28 septembre 2023

Newlife: CSEM part of a ground-breaking European collaboration that is transforming pregnancy care and newborn health with smart textiles and sensors

(Cet article n'est disponible qu'en anglais)
Imagine you or your baby is wearing a T-shirt, a bodysuit, or a cap that can tell you everything you need to know about your pregnancy and your baby’s health. Sounds like science fiction, right? But it is not. This is the reality of CSEM, a partner of the Chips Joint Undertaking funded Newlife project.

Mum holding her new born baby
© Newlife

Newlife project develops smart clothes and devices that can measure vital data from pregnant women and their baby, improving the quality and safety of pregnancy and newborn care. In this article, we rundown the five key things you need to know about CSEM’s role in this project:

1.     We are developing connected sensors with the potential to save lives

These sensors are integrated into clothes such as cuffs, belts, bodysuits, caps, or beds. They can measure various vital signs, including the blood pressure, heart rate, temperature, pH, and oxygenation level of the mother and the baby. They allow pregnant women to monitor their pregnancy from their phone, thanks to an app that connects with the sensors and provides feedback and guidance. They also provide continuous medical monitoring while ensuring maximum data security. CSEM’s teams are now working on ways to make these sensors smaller, lighter, washable, and even more secure.

2.     We are developing fluidics for a test device for early detection of preeclampsia

This device is like a COVID test and can tell if the pregnant woman has preeclampsia in less than 20 minutes during early pregnancy. Preeclampsia is a serious condition that can affect pregnant women and their babies. It means that the blood pressure of the pregnant mother is too high and can cause problems for their organs or baby.

3.     We are co-developing a decision support platform

This platform collects and uses artificial intelligence to understand the data from the different sensors using a common means of communication. It also gives feedback and recommendations to healthcare professionals and parents. This platform shows the health status of the mother and the baby, makes diagnosis faster, and improves reactivity. The platform is being developed in collaboration with Newlife partners.

4.     We collaborate with other Swiss partners in the consortium

CSEM works with other Swiss partners in the Newlife project, such as the Women’s Maternity Clinic (Obstetrics and Gynecology Department) at the University Hospital of Bern (Inselspital). The Inselspital is home to one of the leading maternity centers in Switzerland, providing comprehensive healthcare for its patients, through pioneering quality, research, innovation and education. The Inselspital validates and uses the wearable technologies developed by CSEM in clinical trials and provides it with valuable feedback and insights. Together, we aim to improve the health outcomes of pregnant women and babies. CSEM is also supporting the Swiss start-up MOMM Diagnostics on their early diagnosis preeclampsia test with digital lateral flow. CSEM also leads this Swiss cluster, which includes the Inselspital, MOMM Diagnostics, NANOLEQ, Polar Electro, Zoundream and Rekonas.

5.     We contribute to a global challenge

According to the Born too soon: decade of action on preterm birthreport produced by the World Health Organization (WHO) and the United Nations Children’s Fund (UNICEF) together with Partnership for Maternal, Newborn and Child Health (PMNCH) — the world’s largest alliance for women, children, and adolescents, preterm birth rates have not improved much over the last decade. The average ratio is one premature baby for every 10 births; and one of these premature babies dies every 40 seconds. This data shows how important medical innovations like those developed by the Newlife project are.

©Newlife

What are the benefits and impacts of the project?

The Newlife project aims to improve pregnancy care and newborn health by providing innovative solutions that are user-friendly, cost-effective, and scalable. The project hopes to contribute to reducing maternal and infant mortality and morbidity rates, as well as enhancing the quality of life of mothers and babies.

The Newlife consortium held its semi-annual meeting in June 2023 in Finland, where they discussed the progress and challenges of the project. The next meeting will take place in December 2023 in Switzerland, where all 25 Newlife partners will showcase their achievements and demonstrate their technologies.

More info available at: www.newlife-kdt.eu

Logo CHIPS

This project is supported by the Chips Joint Undertaking (Grant Agreement No. 101095792) and its members Finland, Germany, Ireland, the Netherlands, Sweden, Switzerland. This work includes top-up funding from the Swiss State Secretariat for Education, Research and Innovation (SERI)